
CYTK
Healthcare · Biotechnology · $7.82B market cap
$56.13-0.03 (-0.1%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +3.8% over 90 days · 30-day revisions 6 up, 2 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 4, 2026 | After the close | -1.50 | -1.37 | +8.7% |
| Aug 6, 2026 | After the close | -1.63 | -1.50 | +8.0% |
| May 5, 2026 | After the close | -1.65 | -1.67 | -1.2% |
| Feb 24, 2026 | Time not confirmed | -1.56 | -1.50 | +3.8% |
| Nov 5, 2025 | After the close | -1.59 | -1.54 | +3.1% |
| Aug 7, 2025 | After the close | -1.34 | -1.12 | +16.4% |
| May 6, 2025 | After the close | -1.36 | -1.36 | 0.0% |
| Feb 25, 2025 | After the close | -1.17 | -1.26 | -7.3% |
| Nov 6, 2024 | After the close | -1.24 | -1.36 | -9.7% |
| Aug 8, 2024 | After the close | -0.91 | -1.31 | -44.0% |
| May 8, 2024 | After the close | -1.17 | -1.33 | -13.7% |
| Feb 27, 2024 | After the close | -0.97 | -1.38 | -42.3% |
| Nov 2, 2023 | After the close | -0.76 | -1.35 |
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small…
| -77.6% |
| Aug 2, 2023 | After the close | -1.24 | -1.34 | -8.1% |
| May 4, 2023 | After the close | -1.18 | -1.38 | -16.9% |
| Mar 1, 2023 | After the close | -1.21 | -1.45 | -19.8% |
| Nov 3, 2022 | After the close | -1.17 | -1.28 | -9.4% |
| Aug 4, 2022 | After the close | -1.01 | -0.23 | +77.2% |
| May 4, 2022 | After the close | -0.94 | -1.02 | -8.5% |
| Feb 24, 2022 | After the close | -0.84 | -0.36 | +57.1% |
| Nov 3, 2021 | After the close | -0.77 | -0.95 | -23.4% |
| Aug 5, 2021 | After the close | -0.66 | -0.86 | -30.3% |
| May 6, 2021 | After the close | -0.60 | -0.66 | -10.0% |
| Feb 25, 2021 | After the close | -0.30 | -0.62 | -106.7% |
| Nov 4, 2020 | After the close | -0.34 | -0.05 | +85.3% |
| Aug 6, 2020 | After the close | -0.57 | -0.68 | -19.3% |
| May 6, 2020 | After the close | -0.50 | -0.66 | -32.0% |
| Mar 3, 2020 | After the close | -0.44 | -0.52 | -18.2% |
| Oct 31, 2019 | After the close | -0.49 | -0.50 | -2.0% |
| Aug 8, 2019 | After the close | -0.50 | -0.56 | -12.0% |
| May 9, 2019 | After the close | -0.47 | -0.54 | -14.9% |
| Feb 21, 2019 | After the close | -0.52 | -0.48 | +7.7% |
| Nov 1, 2018 | After the close | -0.52 | -0.40 | +23.1% |
| Jul 26, 2018 | After the close | -0.51 | -0.51 | 0.0% |
| Apr 26, 2018 | After the close | -0.58 | -0.56 | +3.4% |
| Feb 15, 2018 | After the close | -0.70 | -0.75 | -7.1% |